Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as an oral formulation for oral use. It helps to reduce the viscosity of respiratory mucus, facilitates mucociliary clearance, and eases cough in patients with acute or chronic bronchial conditions such as bronchitis and COPD. The drug is indicated for adults and children who experience mucus hyper‑secretion and benefit from improved airway patency.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan (Ambroxol) acts on the respiratory tract to thin and mobilise mucus, supporting the body's natural clearance mechanisms. - Acute bronchitis: reduces mucus thickness and promotes expectoration, helping relieve cough. - Chronic bronchitis: improves sputum clearance and reduces the frequency of productive cough episodes. - Chronic obstructive pulmonary disease (COPD): assists in managing chronic mucus hyper‑secretion and eases breathing. - Respiratory tract infections with mucus hypersecretion: supports symptom relief by enhancing mucociliary transport.

Common Side Effects: - Nausea: mild gastrointestinal discomfort reported by some users. - Taste disturbance: a temporary bitter or metallic taste in the mouth. - Abdominal discomfort: mild stomach pain or cramps. - Diarrhoea: loose stools occurring occasionally. - Headache: mild to moderate headache in a minority of patients. - Skin rash: transient erythema or itching.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis requiring immediate medical attention. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: rare liver function abnormalities. - Eosinophilia: increased eosinophil count indicating hypersensitivity. - Bronchospasm: paradoxical tightening of airway muscles in susceptible individuals. - Hematologic changes: rare cases of neutropenia or thrombocytopenia.

Before using Mucosolvan, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; monitor the infant for adverse effects. - Renal impairment: dosage adjustment may be required in severe kidney dysfunction. - Asthma or reactive airway disease: observe for possible bronchospasm. - Concomitant medications: review all current drugs to avoid interactions. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mucosolvan may interact with several medicines; awareness helps minimise risk. Major Interactions (Avoid): - Codeine‑containing antitussives: may diminish mucolytic efficacy. - Other mucolytics (e.g., N‑acetylcysteine): risk of excessive mucus thinning. - Monoamine oxidase inhibitors (MAOIs): potential for adverse systemic reactions. Moderate Interactions (Monitor Closely): - Bronchodilators (β2‑agonists): may enhance bronchodilatory effect. - Antihistamines: possible increase in sedation or dry mouth. - Macrolide antibiotics: monitor for gastrointestinal upset.